Onesource Specialty Pharma Limited
Onesource Specialty Pharma Ltd. partner Orbicular received Health Canada approval for a generic version of Ozempic® (semaglutide injection). This enables commercialization for the first two generic entrants in Canada's significant semaglutide market, with OneSource supporting manufacturing from its US FDA-approved facility in Bengaluru.
May 04 2026 08:05:00
Onesource Specialty Pharma Limited
Onesource Specialty Pharma Ltd. partner Orbicular received Health Canada approval for a generic version of Ozempic® (semaglutide injection). This enables commercialization for the first two generic entrants in Canada's significant semaglutide market, with OneSource supporting manufacturing from its US FDA-approved facility in Bengaluru.
May 04 2026 08:05:00
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
OneSource Specialty Pharma's partner, Orbicular, received Health Canada approval for a generic version of Ozempic (semaglutide injection). This enables commercialization in Canada's significant market, with OneSource providing manufacturing from its US FDA-approved facility, strengthening its CDMO presence.
May 04 2026 08:05:00
Onesource Specialty Pharma Limited
OneSource Specialty Pharma Limited's partner, Dr. Reddy's Laboratories, received Health Canada approval for its generic Semaglutide Injection. OneSource will serve as the CDMO partner, handling scale-up and commercial manufacturing from its US-FDA approved facility in Bengaluru. This strengthens their collaboration and validates OneSource's manufacturing capabilities.
Apr 29 2026 09:04:00
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Onesource's partner, Dr. Reddy's Laboratories, received Health Canada approval for generic Semaglutide Injection. Onesource will serve as the CDMO partner for scale-up and commercial manufacturing from its US-FDA approved facility in Bengaluru.
Apr 29 2026 09:04:00
Onesource Specialty Pharma Limited
OneSource's Sterile Product Division in Bangalore received an EU GMP Certificate from German authorities. This certification confirms compliance with EU GMP requirements for sterile products, ensuring quality for small volume liquids and testing.
Apr 28 2026 21:04:00
Onesource Specialty Pharma shares gain after equity worth ₹408 crore changes hands in block deals
Onesource Specialty Pharma's partner has received USFDA approval for a generic version of Ozempic, a development that is expected to create new contract manufacturing opportunities for Onesource, impacting its contract development and manufacturing organization (CDMO) services positively.
Apr 21 2026 11:04:00
Onesource Specialty Pharma partner wins tentative USFDA nod for generic Ozempic; Stock falls
OneSource Specialty Pharma has received regulatory approval from Saudi Arabia for its generic version of Ozempic (semaglutide) and will commercialize it with its partner Hikma Pharmaceuticals in the Middle East and North Africa region, leveraging a significant growth opportunity in the GLP-1 market.
Apr 21 2026 09:04:00
Onesource Specialty Pharma Limited
OneSource's partner Orbicular secured tentative U.S. FDA approval for generic Ozempic® (Semaglutide Injection). OneSource acted as the CDMO partner, providing end-to-end manufacturing capabilities. This reinforces OneSource's position in complex pharmaceutical products.
Apr 21 2026 08:04:00
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
OneSource Specialty Pharma's partner Orbicular secured tentative U.S. FDA ANDA approval for generic Ozempic® (Semaglutide Injection). OneSource acted as the CDMO partner, utilizing its US-FDA approved manufacturing site in Bangalore for production.
Apr 21 2026 08:04:00
Read More